FierceBiotechTakeda joins CAR-T chasing pack with Noile-Immune alliance …FierceBiotechWith CAR-T therapies now reaching the market, Japanese drugmaker Takeda has made a play to grab a slice of the pie via a deal with biotech startup …and more&… Continue reading
The Daily Telegram |
FDA clears breakthrough gene therapy for childhood leukemia
The Daily Telegram CAR-T treatment uses gene therapy techniques not to fix disease-causing genes but to turbocharge T cells, immune system soldiers that cancer too often can evade. Researchers filter those cells from a patient’s blood, reprogram them to harbor a … FDA approves first ‘living drug’ for tough childhood leukemiaKTRK-TV FDA announces first US gene therapy approval for cancer treatmentmyfox8.com Breakthrough CAR–T treatment for leukaemia gets FDA nodGears Of Biz |
|
Cell and gene therapies: From clinical to commercial
BioPharma Dive For innovators developing cell and gene therapies, there is a natural flow from clinical trial logistics to commercial logistics. Proactive planning – particularly during the early stages – is vital to establish scalable processes to support patient … |
|
Exploring Immunotherapy for Carcinoid and Pancreatic Neuroendocrine Tumors
Newswise (press release) Newswise — New Brunswick, N.J. – September 5, 2017 – A clinical trial testing the immunotherapy drug pembrolizumab shows the drug to be well tolerated among patients who have carcinoid or pancreatic neuroendocrine tumors. Janice M. Mehnert, MD, … |
|
Exploring Immunotherapy for Carcinoid and Pancreatic Neuroendocrine Tumors
Newswise (press release) Newswise — New Brunswick, N.J. – September 5, 2017 – A clinical trial testing the immunotherapy drug pembrolizumab shows the drug to be well tolerated among patients who have carcinoid or pancreatic neuroendocrine tumors. Janice M. Mehnert, MD, … |